Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Cytamen 1000 mcg Injection

Active Ingredient:
RPH Pharmaceuticals AB See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 13 May 2022
1. Name of the medicinal product

Cytamen 1000 micrograms/mL Injection

2. Qualitative and quantitative composition

Each 1 ml of solution contains: cyanocobalamin 1000 micrograms

3. Pharmaceutical form

Solution for injection (Injection)

4. Clinical particulars
4.1 Therapeutic indications

Addisonian pernicious anaemia. Prophylaxis and treatment of other macrocytic anaemias associated with vitamin B12 deficiency. Schilling test.

Not indicated for treatment of toxic amblyopias - use Neo-Cytamen.

4.2 Posology and method of administration

Route of administration: intramuscular.

Adults and Children

Addisonian pernicious anaemia and other macrocytic anaemias without neurological involvement:

Initially: 250 to 1000mcg intramuscularly on alternate days for one to two weeks, then 250mcg weekly until the blood count is normal.

Maintenance: 1000mcg monthly.

Addisonian pernicious anaemia and other macrocytic anaemias with neurological complications:

Initially: 1000mcg intramuscularly on alternate days as long as improvement is occurring.

Maintenance: 1000mcg monthly.

Prophylaxis of macrocytic anaemia associated with vitamin B12 deficiency resulting from gastrectomy, some malabsorption syndromes and strict vegetarianism:

250mcg - 1000mcg monthly.

Schilling Test:

An intramuscular injection of 1000mcg cyanocobalamin is an essential part of this test.

4.3 Contraindications

Hypersensitivity to cyanocobalamin or any other constituents

Cytomen should not be used for the treatment of megaloblastic anaemia of pregnancy unless vitamin B12 deficiency has been demonstrated.

Not indicated for treatment of toxic amblyopias - use Neo-Cytamen.

4.4 Special warnings and precautions for use


The dosage schemes given above are usually satisfactory, but regular examination of the blood is advisable. If megaloblastic anaemia fails to respond to Cytamen, folate metabolism should be investigated. Doses in excess of 10mcg daily may produce an incomplete haematological response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis. The haematological and neurological state should be monitored regularly to ensure adequacy of therapy. Cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported. Plasma potassium should therefore be monitored during this period. Platelet count should be monitored during the first weeks of use in megaloblastic anaemia due to the possible occurrence of reactive thrombocytosis.

This medicine contains less than 1mmol (23mg) sodium per dose, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

Chloramphenicol-treated patients may respond poorly to Cytamen. Serum concentrations of cyanocobalamin may be lowered by oral contraceptives but this interaction is unlikely to have clinical significance.

Antimetabolites and most antibiotics invalidate vitamin B12 assays by microbiological techniques.

4.6 Pregnancy and lactation

Cytamen should not be used for the treatment of megaloblastic anaemia of pregnancy unless vitamin B12 deficiency has been demonstrated. Cytamen is secreted into breast milk but this is unlikely to harm the infant, and may be beneficial if the mother and infant are vitamin B12 deficient.

4.7 Effects on ability to drive and use machines


4.8 Undesirable effects

Hypersensitivity reactions have been reported including skin reactions (e.g. rash, itching) and exceptionally anaphylaxis. Other symptoms reported include fever, chills, hot flushing, dizziness, malaise, nausea, acneiform and bullous eruptions, tremor and injection site reactions including injection site pain, injection site induration and injection site necrosis. Reactive thrombocytosis can occur during the first weeks of use in megaloblastic anaemia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Treatment is unlikely to be needed in cases of overdosage.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Cyanocobalamin is a form of vitamin B12.

5.2 Pharmacokinetic properties

Cobalamins are absorbed from the gastro-intestinal tract, but may be irregularly absorbed when given in large therapeutic doses. Absorption is impaired in patients with an absence of intrinsic factor, with a malabsorption syndrome or with a disease or abnormality of the gut, or after gastrectomy.

After injection of cyanocobalamin a large proportion is excreted in the urine within 24 hours; the body retains only 55% of a100-microgram dose and 15% of a 1000-microgram dose. Vitamin B12 is extensively bound to specific plasma proteins called transcobalamins; transcobalamin II appears to be involved in the rapid transport of the cobalamins to tissues. Vitamin B12 is stored in the liver, excreted in the bile, and undergoes extensive enterohepatic recycling; part of an administered dose is excreted in the urine, most of it in the first 8 hours; urinary excretion, however, accounts for only a small fraction in the reduction of total body stores acquired by dietary means. Vitamin B12 diffuses across the placenta and also appears in breast milk.

5.3 Preclinical safety data

None stated.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium chloride

Acetic acid

Water for injections

6.2 Incompatibilities


6.3 Shelf life

18 months.

6.4 Special precautions for storage

Protect from light. Do not store above 25° C

6.5 Nature and contents of container

1ml clear, one-point cut (OPC) colourless glass Type 1 Ph Eur ampoules packed in cartons of 5 ampoules

6.6 Special precautions for disposal and other handling

None stated.

7. Marketing authorisation holder

RPH Pharmaceuticals AB

Box 603

101 32 Stockholm


8. Marketing authorisation number(s)

PL 36301/0010

9. Date of first authorisation/renewal of the authorisation

17/12/1992 / 31/01/2003

10. Date of revision of the text


RPH Pharmaceuticals AB
Company image
Box 603, 101 32 Stockholm, Sweden
+44 (0)845 023 0467
Medical Information Direct Line
+44 207 862 1716
Medical Information e-mail
[email protected]
Customer Care direct line
+44(0)845 023 0467
Stock Availability
+44(0)845 023 0467